Predict your next investment

Corporation
novonordisk.com

See what CB Insights has to offer

Investments

22

Portfolio Exits

9

Partners & Customers

10

Service Providers

1

About Novo Nordisk

Novo Nordisk is a healthcare company that specializes in diabetes care. It also operates in haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

Novo Nordisk Headquarter Location

Novo Alle

Bagsvaerd, 2880,

Denmark

+45 4444 8888

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Novo Nordisk

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Novo Nordisk in 5 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

3

3D Printing

411 items

D

Diabetes

1,750 items

C

Conference Exhibitors

5,302 items

M

Medical Devices

3,500 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Latest Novo Nordisk News

Early referral for ablation may be needed for certain patients with AF

Jan 27, 2022

Healio Commentary Disclosures: Granger reports receiving consultant honoraria and/or research grant support from AbbVie, Alnylam, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Celecor, Daiichi Sankyo, Eli Lilly, Hengrui, Janssen, Medtronic, Merck, the NIH, Novartis, Novo Nordisk, Philips, Pfizer, Reata and the FDA. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio By 2030, the number of people in the United States with atrial fibrillation will double to more than 12 million, making it imperative that patients receive the best treatments to improve outcomes and functional status. For controlling the rhythm for symptomatic patients with AF, drug therapy has been the standard of care, but antiarrhythmic drugs are failing in more than half of patients. Only after drugs have failed will many patients go on to have a catheter ablation. Because AF can limit a person’s ability to carry on with daily activities, like climbing the stairs or walking down the driveway to the mailbox, delaying a patient’s time to ablation not only allows for disease progression but may reduce their overall quality of life. Christopher B. Granger, MD, is professor of medicine at Duke University School of Medicine and member in the Duke Clinical Research Institute. Comprehensive treatment of AF with oral anticoagulation, addressing comorbidities, rate control and rhythm control are essential to improving symptoms, preventing stroke and HF, reducing hospitalizations and improving survival. The evidence for the timing and type of rhythm control has advanced over the past few years. Shifting the paradigm in AF treatment Looking back just 2 or 3 years ago, the way I treated patients with AF was completely different. I considered ablation to be a last resort or an option only for those with recurring symptoms after antiarrhythmic drug treatment. Now, for the first time, the results of three randomized clinical trials — Cryo-FIRST, EARLY-AF and STOP AF First — provide clear evidence for how and when to best control rhythm: they show that ablation and, particularly, cryoablation — ablation with a cryoballoon catheter (Arctic Front Advance, Medtronic) — as a first-line treatment is a proven, evidence-based initial rhythm control strategy to reduce atrial arrhythmia recurrence and improve patient outcomes. In June, the FDA granted a new indication to cryoballoon catheter ablation , permitting it to be used before antiarrhythmic drugs in certain patients with AF. As a general cardiologist, I see a broad spectrum of patients every week with symptoms of AF. This includes friends, colleagues and members of my community, and for each one of them, I now can confidently present ablation, including cryoablation, as the most effective treatment to maintain sinus rhythm and improve their quality of life, even before trying any antiarrhythmic drug therapy. For many of my patients, the journey of AF care with ablation begins with some type of monitoring device. For example, a woman at Duke in her mid-60s originally received a heart monitor to track her heart palpitations. She called me one night because she was presenting with symptoms and sent me her rhythm strips, which showed AF on her device for hours at a time. After a conversation about creating a treatment plan, I referred her to get an ablation — ultimately leaving her feeling assured knowing we caught the disease early and that she was on course for the most effective treatment. Within 4 months of when her symptoms began, she received an ablation and is getting back to her everyday life. Managing misconceptions To achieve these better outcomes for patients and offer the best course of care possible, it is important to understand how the management of AF has changed over the last several years, address the misconceptions that exist, and educate on why ablation, and in particular cryoablation, is a safe and effective initial treatment option: Many symptomatic patients will benefit from an initial rhythm control strategy: Compared with previous notions, there has been mounting evidence over the past few years that show a rhythm control strategy provides benefits to prevent ongoing and worsening symptoms for patients with symptomatic AF. This is also consistent with the 2020 European Society of Cardiology Clinical Practice Guidelines for Atrial Fibrillation. Ablation is quite safe: Recent evidence shows us that current state-of-the-art ablation, including cryoablation, is not only effective but has few complications. Now safety concerns are a minimal barrier for considering ablation as the first step in a patient’s treatment course. Ablation is the optimal initial strategy for many patients: Ablation should not just be a backup strategy for patients who tried multiple drugs or cardioversions. We now have evidence for ablation as the best initial strategy for maintaining sinus rhythm and improving quality of life. Monitoring technology has dramatically improved: With the latest monitoring technology, including use of consumer devices to record AF , we can now determine if patients with symptoms of AF have substantial AF much faster than before. With today’s improved AF detection solutions, combined with cryoablation as an initial treatment strategy, our patients have the potential to see better outcomes related to faster diagnosis compared with several years ago. Early referral for many symptomatic patients It is important that we communicate clearly to patients about the best treatment options early after diagnosis of AF. As general cardiologists, this means having conversations with our patients about how to manage their condition, depending on their symptoms and burden of AF. For the millions of patients with AF that we see in our practice as general cardiologists, we have the ability to guide them to the best care to improve their quality of life and to prevent hospitalizations. As a key part of the referral process, it is important to take a team-based approach, with referral of the patient with recent-onset symptomatic AF to electrophysiology colleagues who can offer ablation for the many patients for whom this is the best initial treatment option. References:

Novo Nordisk Investments

22 Investments

Novo Nordisk has made 22 investments. Their latest investment was in Glooko as part of their Series D on March 3, 2021.

CBI Logo

Novo Nordisk Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/16/2021

Series D

Glooko

$30M

Yes

4

2/10/2021

Unattributed

Nordic Mentor Network of Entrepreneurship

$2.17M

Yes

1

10/29/2019

Series A

Disc Medicine

$50M

Yes

7

4/30/2019

Pre-Seed

Subscribe to see more

Subscribe to see more

10

11/12/2018

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/16/2021

2/10/2021

10/29/2019

4/30/2019

11/12/2018

Round

Series D

Unattributed

Series A

Pre-Seed

Convertible Note

Company

Glooko

Nordic Mentor Network of Entrepreneurship

Disc Medicine

Subscribe to see more

Subscribe to see more

Amount

$30M

$2.17M

$50M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

1

7

10

10

Novo Nordisk Portfolio Exits

9 Portfolio Exits

Novo Nordisk has 9 portfolio exits. Their latest portfolio exit was Berkeley Lights on July 17, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/17/2020

IPO

$99M

3

8/1/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/26/2016

IPO

Subscribe to see more

$99M

Subscribe to see more

10

12/18/2014

Reverse Merger

Subscribe to see more

Subscribe to see more

10

9/12/2014

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/17/2020

8/1/2019

5/26/2016

12/18/2014

9/12/2014

Exit

IPO

IPO

IPO

Reverse Merger

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

10

10

10

10

Novo Nordisk Acquisitions

11 Acquisitions

Novo Nordisk acquired 11 companies. Their latest acquisition was Dicerna Pharmaceuticals on December 28, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/28/2021

Series C

$99M

$123.8M

Take Private

7

7/12/2021

$99M

Acquired

1

12/8/2020

$99M

Merger

3

6/11/2020

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/12/2018

Series E+

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

12/28/2021

7/12/2021

12/8/2020

6/11/2020

12/12/2018

Investment Stage

Series C

Series B

Series E+

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$123.8M

$99M

$99M

Note

Take Private

Acquired

Merger

Subscribe to see more

Subscribe to see more

Sources

7

1

3

10

10

Novo Nordisk Partners & Customers

10 Partners and customers

Novo Nordisk has 10 strategic partners and customers. Novo Nordisk recently partnered with CVS Health on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/17/2021

Partner

CVS Health

United States

1

6/29/2021

Partner

Walmart

United States

Walmart teams up with Novo Nordisk to launch private-brand analog insulin

Walmart teams up with Novo Nordisk to launch private-brand analog insulin

1

6/29/2021

Vendor

NNIT

Denmark

NNIT A/S: 07/2021 The NNIT Group renews infrastructure management agreement with Novo Nordisk and adjusts the company’s financial outlook

Ricco Larsen , Senior Vice President , Life Sciences at NNIT says about the agreement : `` We are pleased to continuously be able to meet Novo Nordisk 's high expectations and extend the agreement '' .

1

6/16/2021

Vendor

Harbour BioMed

China

Subscribe to see more

Subscribe to see more

10

6/16/2021

Partner

Amalgam Rx

United States

Subscribe to see more

Subscribe to see more

10

Date

9/17/2021

6/29/2021

6/29/2021

6/16/2021

6/16/2021

Type

Partner

Partner

Vendor

Vendor

Partner

Business Partner

CVS Health

Walmart

NNIT

Harbour BioMed

Amalgam Rx

Country

United States

United States

Denmark

China

United States

News Snippet

Walmart teams up with Novo Nordisk to launch private-brand analog insulin

Walmart teams up with Novo Nordisk to launch private-brand analog insulin

NNIT A/S: 07/2021 The NNIT Group renews infrastructure management agreement with Novo Nordisk and adjusts the company’s financial outlook

Ricco Larsen , Senior Vice President , Life Sciences at NNIT says about the agreement : `` We are pleased to continuously be able to meet Novo Nordisk 's high expectations and extend the agreement '' .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Novo Nordisk Service Providers

1 Service Provider

Novo Nordisk has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Merger

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Merger

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Novo Nordisk Team

23 Team Members

Novo Nordisk has 23 team members, including current Chief Executive Officer, President, Lars Rebien Soerensen.

Name

Work History

Title

Status

Lars Rebien Soerensen

Chief Executive Officer, President

Current

Pal Helmich

Rohm and Haas Company

President

Current

Todd Hobbs MD

Chief Medical Officer

Current

Alan Moses

Chief Medical Officer, Senior Vice President

Current

Jesper Brandgaard

Executive Vice President

Current

Name

Lars Rebien Soerensen

Pal Helmich

Todd Hobbs MD

Alan Moses

Jesper Brandgaard

Work History

Rohm and Haas Company

Title

Chief Executive Officer, President

President

Chief Medical Officer

Chief Medical Officer, Senior Vice President

Executive Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.